Grufity logoGrufity logo

SURF

1.00USD+0.02(+2.04%)Market Closed

Surface Oncology Inc

Market Summary

USD1.00+0.02Market Closed
2.04%

SURF Stock Price

RSI Chart

Valuation

Market Cap

73.1M

Price/Earnings

-1.16

Price/Sales

22.68

Price/Cashflow

-1.46

MarketCap/EBT

-0.78

Price/Sales

Profitability

EBT Margin

-2920.92%

Return on Equity

-50.08%

Return on Assets

-32.46%

Fundamentals

Revenue

Revenue Y/Y

-100%

Revenue Q/Q

-100%

Earnings

Earnings (TTM)

-66.3M

Earnings Y/Y

-16.83%

Earnings Q/Q

7.83%

Price Action

52 Week Range

0.925.98
(Low)(High)

Last 7 days

-2.0%

Last 30 days

-11.5%

Last 90 days

-34.6%

Trailing 12 Months

-82.3%

Financial Health

Current Ratio

8.19

Investor Care

Shares Dilution (1Y)

31.23%

Diluted EPS (TTM)

-1.24

Peers (Alternatives to Surface Oncology)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
7.14% 43.50%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
8.82% 22.00%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
7.16% 39.03%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-6.88% -45.94%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-4.89% -63.56%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
-5.28% -44.88%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-21.14% -78.94%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
12.62% -35.50%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-18.16% -60.18%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-23.83% -90.20%
-13.56
44.06
522.71% -129.91%
218.9M
-
-24.71% -82.02%
-2.36
609.63
-71.03% -64.56%

Financials for Surface Oncology

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
RevenueNaN%nullnullnull2,687,00033,555,750
Operating Expenses3.3%94,213,00091,199,00085,678,00078,700,00074,772,000
  S&GA Expenses0.6%26,175,00026,018,00026,026,00025,128,00026,794,000
  R&D Expenses4.4%68,038,00065,181,00059,652,00053,572,00047,978,000
Earnings Before Taxes--78,485,000.00
Net Income-5.3%-66,304,000.00-62,957,000.00-56,725,000.00-78,485,000.0012,913,000
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-6.4%182194218191189
  Current Assets-7.0%150162184157155
    Cash Equivalents-13.0%6575665661
  Net PPE-5.3%55566
Liabilities0.8%6968717257
  Current Liabilities-8.8%1820202016
Shareholder's Equity-10.3%113126147119131
  Retained Earnings-14.5%-183.00-159.76-134.54-140.74-116.69
  Additional Paid-In Capital3.7%297287282260248
Accumulated Depreciation-8----
Shares Outstanding9.3%6155544646
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-7.1%-53.65-50.09-66.95-62.3426
  Share Based Compensation-3.6%88899
Cashflow From Investing280.4%5-3.03-16.15-99.25-86.51
Cashflow From Financing17.5%5245484322

Risks

What is the probability of a big loss on SURF?

94.7%


Probability that Surface Oncology stock will be more than 20% underwater in next one year

94.2%


Probability that Surface Oncology stock will be more than 30% underwater in next one year.

93%


Probability that Surface Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SURF drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.

Returns

Cumulative Returns on SURF

-21.1%


3-Year Cumulative Returns

Which funds bought or sold SURF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-3,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-97.2
-27,136
491
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
11,000
11,000
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
-103,000
178,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-14
GSA CAPITAL PARTNERS LLP
-
-
26,000
125,000
0.02%
2022-11-14
BlackRock Inc.
-
-
-626,000
1,068,000
-%
2022-11-14
DAFNA Capital Management LLC
-
-
-660,000
1,144,000
0.31%
2022-11-14
Laurion Capital Management LP
-
-
-399,000
692,000
-%
2022-11-14
EcoR1 Capital, LLC
REDUCED
-15.65
-3,549,000
4,082,000
0.12%

1–10 of 45

Latest Funds Activity

Are funds buying SURF calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SURF

Surface Oncology News

Simply Wall St

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically.21 days ago

SURF Fair Value

Recent SEC filings of Surface Oncology

View All Filings
Date Filed Form Type Document
Nov 03, 2022
4
Insider Trading
Nov 03, 2022
3
Insider Trading
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Sep 23, 2022
8-K
Current Report

Latest Insider Trading transactions for SURF

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-03
FEES JESSICA
SOLD
-10,285.6
1.72
-5,980
Chief Financial Officer
2022-08-03
ROSS ROBERT W.
SOLD
-18,221.7
1.72
-10,594
Chief Executive Officer
2022-08-03
RATH HENRY C.
SOLD
-9,762.72
1.72
-5,676
Chief Business Officer
2022-08-03
Palombella Vito J.
SOLD
-7,676.36
1.72
-4,463
Chief Scientific Officer
2022-08-03
ONEILL ALISON
SOLD
-7,676.36
1.72
-4,463
Chief Medical Officer
2022-03-01
FEES JESSICA
ACQUIRED
-
-
38,000
Chief Financial Officer
2022-03-01
ONEILL ALISON
ACQUIRED
-
-
38,000
Chief Medical Officer
2022-03-01
ROSS ROBERT W.
ACQUIRED
-
-
56,000
Chief Executive Officer
2022-03-01
RATH HENRY C.
ACQUIRED
-
-
38,000
Chief Business Officer
2022-03-01
Palombella Vito J.
ACQUIRED
-
-
38,000
Chief Scientific Officer

1–10 of 50

Robert W. Ross
70
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

SURF Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]    
License-related revenue$ 0$ 392$ 30,000$ 2,532
Operating expenses:    
Research and development16,89414,03751,71537,250
General and administrative6,0045,84718,97017,923
Total operating expenses22,89819,88470,68555,173
Loss from operations(22,898)(19,492)(40,685)(52,641)
Interest expense(829)(421)(2,244)(1,861)
Other income (expense), net4872067567
Net loss$ (23,240)$ (19,893)$ (42,254)$ (54,435)
Net loss per share attributable to common stockholders— basic (in dollars per share)$ (0.39)$ (0.44)$ (0.78)$ (1.25)
Net loss per share attributable to common stockholders— diluted (in dollars per share)$ (0.39)$ (0.44)$ (0.78)$ (1.25)
Weighted average common shares outstanding— basic (in shares)59,054,48645,236,77554,143,39443,510,078
Weighted average common shares outstanding— diluted (in shares)59,054,48645,236,77554,143,39443,510,078
Comprehensive loss:    
Net loss$ (23,240)$ (19,893)$ (42,254)$ (54,435)
Other comprehensive loss:    
Unrealized (loss) gain on marketable securities, net of tax of $0(199)6(1,148)(3)
Comprehensive loss$ (23,439)$ (19,887)$ (43,402)$ (54,438)

SURF Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 65,096$ 56,045
Marketable securities81,25498,104
Prepaid expenses and other current assets3,7723,197
Total current assets150,122157,346
Property and equipment, net4,9255,651
Operating lease right-of-use asset24,88825,870
Restricted cash1,5951,595
Other assets91385
Total assets181,621190,847
Current liabilities:  
Accounts payable5351,550
Accrued expenses and other current liabilities11,70013,089
Operating lease liability5,7575,384
Convertible note payable00
Total current liabilities17,99220,023
Operating lease liability, non-current25,34826,909
Convertible note payable, non-current25,46225,015
Total liabilities68,80271,947
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized    at September 30, 2022 and December 31, 2021; no shares    issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.0001 par value; 150,000,000 shares    authorized at September 30, 2022 and December 31, 2021, respectively;    60,542,261 and 46,958,776 shares issued and outstanding at September 30, 2022    and December 31, 2021, respectively65
Additional paid-in capital297,179259,859
Accumulated other comprehensive loss(1,369)(221)
Accumulated deficit(182,997)(140,743)
Total stockholders’ equity112,819118,900
Total liabilities and stockholders’ equity$ 181,621$ 190,847